> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Neurocrine’s Crenessity for CAH
- URL: https://www.fdaweb.com/fda-approves-neurocrines-crenessity-for-cah/
- Published: 2025-01-03T12:00:00.000Z
- Updated: 2026-09-14T14:49:59.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158397

FDA has approved Neurocrine Bioscience’s Crenessity (crinecerfont) to be used with glucocorticoids to control androgen in adults and pediatric patients aged 4 and older with classic congenital adrenal hyperplasia (CAH). An agency [statement](https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-congenital-adrenal-hyperplasia?ref=fdaweb.com) says the Crenessity approval was based on two trials in 182 adults and 103 children with classic CAH.

The drug has a Warning for acute adrenal insufficiency or adrenal crisis, which can occur in patients with underlying adrenal insufficiency who do not also receive adequate doses of glucocorticoid replacement therapy in situations associated with increased cortisol need.

The most common side effects of Crenessity in adults include fatigue, dizziness, and arthralgia, FDA says. For pediatric patients, the most common side effects are headache, abdominal pain, and fatigue.

The agency granted Crenessity fast track, breakthrough therapy, and orphan drug designations and gave it priority review.